Eric R. Olson - 05 Jan 2022 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: SYRS
Reported as of: 05 Jan 2022
Net transaction value: -$7,655
SEC form: 4
Accepted by SEC: 06 Jan 2022, 16:02:50 UTC
Prior SEC filing: 01 Jul 2021
Next SEC filing: 17 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Gerald E. Quirk, as attorney-in-fact

Key filing fact

Eric R. Olson filed Form 4 for Syros Pharmaceuticals, Inc. (SYRS) on 06 Jan 2022.

Key facts

This page summarizes Eric R. Olson's Form 4 filing for Syros Pharmaceuticals, Inc. (SYRS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 06 Jan 2022, 16:02.

Change

Previous filing in this sequence was filed on 01 Jul 2021.
Current net transaction value: -$7,655.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRS transaction

Common Stock

Sale

Transaction value: $7,655
Shares: -2,208
Change %: -100%
Price: $3.47
Shares after: 0
Date: 05 Jan 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.44 to $3.49, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.